Abstract
Bristol-Myers Squibb is involved in the research and development of treatments
for conditions such as heart disease, high blood pressure, stroke, diabetes,
cancer, HIV/AIDS, depression, schizophrenia and pain. This report provides a
full review of the company's activities together with sales forecasts for key
products to 2010.
Headquartered in New York, Bristol-Myers Squibb (BMS) is involved in the
research and development of treatments for conditions such as heart disease,
high blood pressure, stroke, diabetes, cancer, HIV/AIDS, depression,
schizophrenia and pain. The company's research and development efforts are
principally focused on Oncology, Affective (Psychiatric) Disorders and
Metabolics.
Current Growth Drivers
- Plavix (clopidogrel), a platelet aggregation inhibitor, is BMS' largest
selling product and continues to make substantial year-on-year sales growth.
The product benefits from co-development and co-commercialisation with
sanofi-aventis in a number of markets worldwide. Since its first approval in
1997, Plavix has been prescribed for around 48 million patients.
- Similarly, Avapro/Avalide (irbesartan), an angiotensin II receptor agonist
indicated for the treatment of hypertension and diabetic neuropathy, was
co-developed and co-marketed with sanofi-aventis in several markets and also
has demonstrated steady market gains since its launch.
- Abilify (aripiprazole), indicated for the treatment of schizophrenia and
related conditions, is the company's flagship Affective Disorders product. The
product was licensed from Otsuka, with whom BMS co-promotes Abilify in several
markets, and has made strong sales increases since it became part of BMS'
product portfolio.
- Erbitux (cetuximab) was licensed from ImClone Systems to become BMS' first
biological product. It is used in the treatments of various cancers and in
March 2006, it became the first new treatment for squamous cell head and neck
cancer in nearly three decades.
- Reyataz (atazanavir), a potent azapeptide inhibitor of HIV protease, is
the first once-daily protease inhibitor to be approved by the FDA. In 2005, it
demonstrated the most significant growth of BMS' pharmaceutical products, with
sales increasing by nearly 70 per cent from the previous year.
Table of Contents
Principal Operating Results
Latest Results
EXECUTIVE SUMMARY
- Introduction
- Current Growth Drivers
- Key Late-Stage Products
- Financial Performance 2005
- Sales and Market Position
- Income
- Sales, Costs and Operating Income, 2005
- Expenditure
- Capital Expenditure
- Capital Expenditure By Business Area
- Capital Expenditure By Business Area, 2005
- R&D Expenditure
- R&D Expenditure and Capital Expenditure
- Divisional Performance
- Sales By Business Segment
- Sales By Business Segment, 2005
- Operating Income By Business Segment
- Operating Income By Business Segment
- Year-End Assets By Business Segment
- Year-End Assets by Business Segment, 2005
- Geographic Performance
- Sales By Geographic Area
- Sales By Geographic Area, 2005
- Year-End Assets By Geographic Area
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Production
- Employees
- Product / R&D Overview
- Key Products
- Recent Product Launches
- Recent Product Approvals
- Discontinued Products
- UFT
- R&D Strategy
- R&D Pipeline Overview
- Discontinued R&D projects
- Basulin
- E2F Decoy
- Ravuconazole (BMS-207147, ER-30346)
- Sales Forecasts
- Sales of Major Product (2000A-2010E)
- Conclusions
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT
- Major Products, Therapeutic Areas and Sales
- Top Selling Products, 2005
- R&D Pipeline
- Cardiovascular - Products
- Major Launched Products
- Avapro/Avalide
- Sales
- Key Markets/Indications/Formulations
- Competitor Products
- Patents/Generic Competition
- Sales Forecast
- Avapro/Avalide Sales (2000A-2010E)
- Plavix/Iscover
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Patents
- Lawsuits/Generic Competition
- Safety Issues
- Sales Forecast
- Plavix/Iscover Sales (2000A-2010E)
- Pravachol
- Sales
- Key Markets/Indications/Formulations
- Competitor Products
- Patents/Generic Competition
- Sales Forecast
- Pravachol Sales (2000A-2010E)
- Others
- Cardiovascular - R&D
- Lumaxis
- Razaxaban (BMS-561389)
- Cardiovascular - Summary
- Growth Potential
- Limiting Factors
- Virology - Products
- Major Launched Products
- Baraclude
- Reyataz
- Sales
- Key Markets/Indications
- Competitor Products
- Patents
- Sales Forecast
- Reyataz Sales (2000A-2010E)
- Sustiva
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Patents/Generic Competition
- Safety Issues
- Sales Forecast
- Sustiva Sales (2000A-2000E)
- Zerit
- Sales
- Key Markets/Indications/Formulations
- Safety Issues
- Competitor Products
- Patents/Generic Competition
- Sales Forecast
- Zerit Sales (2000A-2010E)
- Others
- Virology - R&D
- AI-183 (DPC 083)
- BMS-488043
- Virology - Summary
- Growth Potential
- Limiting Factors
- Oncology - Products
- Major Launched Products
- Erbitux
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Patents
- Lawsuits
- Safety Issues
- Sales Forecast
- Erbitux Sales (2000A-2010E)
- Clinical Trial Results - NSCLC
- Clinical Trial Results - Metastatic Colorectal Carcinoma
- Clinical Trial Results - Head and Neck Cancer
- Clinical Trial Results - Ovarian Cancer
- Taxol
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Patents/Generic Competition
- Lawsuits
- Lawsuits - IVAX/American BioScience/BMS
- Sales Forecast
- Taxol Sales (2000A-2010E)
- Clinical Trial Results - Taxol and Herceptin
- Others
- Oncology - R&D
- BMS-184476
- BMS-214662
- BMS-247616/BMS-247615
- BMS-66513
- Dasatinib
- Discodermolide
- Ipilimumab
- Ixabepilone (BMS-247550)/BMS-310705
- Javlor
- Src/ABL kinase inhibitor
- Oncology - Summary
- Growth Potential
- Limiting Factors
- Affective Disorders - Products
- Major Launched Products
- Abilify
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Patents
- Safety Issues
- Sales Forecast
- Abilify Sales (2000A-2010E)
- Emsam
- Key Markets/Indications/Formulations
- Clincial Trial Results
- Others
- Affective Disorders - R&D
- Affective Disorders - Summary
- Metabolics - Products
- Major Launched Products
- Glucophage franchise
- Sales
- Key Markets/Indications/Formulations
- Safety Issues
- Patents/Generic Competition
- Sales Forecast
- Glucophage Franchise Sales (2000A-2010E)
- Metabolics - R&D
- DPP4 inhibitor
- Inhaled insulin
- Pargluva
- Saxagliptin
- SLV319
- Metabolics - Summary
- Others - Products
- Orencia
- Key Markets/Indications/Formulations
- Further Development
- Patents/Lawsuits
- Clinical Trial Results
- Others - R&D
- Belatacept
- BMS-068645
- BMS-203522
- BMS-249524/BMS-411886/BMS-461996
- BMS-347070
- LFA-1 receptor antagonists
- p38 kinase inhibitor
- Pro-Dafalgen
APPENDIX 1 - FINANCIAL PERFORMANCE
- Full Year Results 2005
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
APPENDIX 2 - KEY CORPORATE EVENTS
APPENDIX 3 - KEY AGREEMENTS
- Adenosine Therapeutics LLC
- Ariad Pharmaceuticals Inc
- Celltech Chiroscience
- Celltrion Inc
- Chiron Corporation
- Domantis Inc
- Elan Corporation Plc
- 20th August 1996
- 8th July 1997
- 22nd December 1998
- 30th September 2003
- Elixir Pharmaceuticals
- Exelixis Inc
- 18th July 2001
- 12th December 2001
- 5th August 2002
- 18th December 2003
- 6th December 2005
- Genzyme Transgenics Corp (GTC)
- 8th September 1997
- 30th November 1999
- 9th January 2001
- Gilead Sciences Inc
- GPC Biotech Inc
- 7th December 1995
- 12th December 2001
- ImClone Systems
- 19th September 2001
- 29th October 2001
- 5th March 2002
- 12th March 2004
- 3rd April 2006
- Intra-Cellular Therapies Inc (ICT)
- Janssen/Neurocrine Biosciences Inc
- Kyorin Pharmaceutical Co Ltd
- Lexicon Genetics Incorporated
- 19th August 1998
- 26th September 2000
- 18th October 2000
- 18th December 2003
- Medarex Inc
- 15th June 1998
- 13th January 2005
- 15th November 2005
- Merck & Co
- February 1997
- 30th March 1999
- 20th December 1999
- Merck Santé SAS
- Nerviano Medical Sciences
- Novartis
- 18th October 2000
- 28th March 2001
- Otsuka/Taiho Pharmaceutical Co Ltd
- Oncology agreement
- Aripiprazole agreement
- 21st September 1999
- OXiGENE Inc
- 6th January 2004
- Pierre Fabre Médicament
- 20th April 2004
- sanofi-aventis
- Shionogi
- Solvay
- Spectrum Pharmaceuticals Inc
- 5th November 2001
- 11th January 2002
- Sunesis Pharmaceuticals
- Licensing
- Co-promotion/Co-marketing
- Discontinued Agreements
- Corgentech Inc
- Flamel Technologies SA
- Merck & Co
- 28th April 2004
- 16th May 2004
- 22nd December 2005
- Qdose
- 10th September 2003
- 7th December 2005
APPENDIX 4 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES
- Subsidiaries
- Major North American Subsidiaries
- Major European Subsidiaries
- Major South American Subsidiaries
- Major Asia/Pacific Region Subsidiaries
- Joint-Venture Companies
APPENDIX 6 - PRODUCT INDEX
|
